Merck
Merck on the march in Africa
December 21, 2015Sales and Marketing Africa, Merck, marketing, sales, strategy
When Merck unveiled its Africa 2020 strategy in November, there was no shortage of ambition.The company announced plans to expand …
Eisai’s Halaven shown to restrict further cancer metastasis
December 11, 2015Research and Development, Sales and Marketing Eisai, Halaven, Merck, keytruda
New data presented by Eisai supports the previously shown ability of Halaven (eribulin) to reverse epithelial-to-mesenchymal transition, the process by …
Merck/Pfizer Alliance to collaborate on late-stage cancer trials
December 10, 2015Research and Development Merck, Pfizer, avelumab, collaboration, gastric cancer, oncology, partnership, stomach cancer
Merck and Pfizer are partnering to run two Phase III trials of avelumab, an immuno-oncology treatment the companies hope to …
Late-stage failure for Merck and Threshold cancer drug
December 7, 2015Research and Development, Sales and Marketing Merck, Pancreatic cancer, Threshold Pharmaceuticals, evofosfamide, late-stage failure, phase III, sarcoma
Merck and its development partner Threshold Pharmaceuticals say they will not pursue regulatory approval for evofosfamide in advanced soft tissue …
Lilly and Merck extend immuno-oncology collaboration
November 20, 2015Medical Communications, Research and Development Eli Lilly, Merck
Eli Lilly and Merck have announced the extension of their existing collaboration to evaluate the safety and efficacy of the …
Merck KGaA completes $17bn Sigma-Aldrich acquisition
November 18, 2015Manufacturing and Production, Sales and Marketing M&A Sigma Aldridge, Merck, acquisitions, mergers
Merck KGaA has announced the completion of its $17 billion acquisition of Sigma-Aldrich, having cleared the final regulatory hurdle and …
Merck achieves 7% sales growth in Q3 2015
November 12, 2015Sales and Marketing Merck, Rebif, financial results
German pharma group Merck has earned a 7% bump in its sales, and a 10% boost in earnings before deductions, …
Merck and Pfizer begin new Phase III avelumab trial in lung cancer
November 5, 2015Medical Communications, Research and Development Merck, Pfizer, avelumab, lung cancer, non-small cell lung cancer
Merck and Pfizer have commenced an international Phase III study of the investigational cancer immunotherapy avelumab in patients with non-small …
Merck appoints Laszlo Radvanyi as head of global immuno-oncology research
November 4, 2015Research and Development Laszlo Radvanyi, Merck
Dr Laszlo Radvanyi has joined Merck as senior vice president and head of research in immuno-oncology. The Merck Group says …
GSK and Merck to study immunotherapy combo in solid tumours
November 3, 2015Research and Development GSK, Merck, immunooncology, immunotherapy, keytruda, phase I
GSK and Merck will start a Phase I clinical trial in humans to evaluate GSK’s investigational cancer drugs with the …
Merck and Selvita form oncology partnership
November 2, 2015Research and Development, Sales and Marketing Merck, Selvita, collaboration, oncology
Merck has entered a three-year agreement with Selvita to validate new therapeutic concepts in the field of oncology. The aim …
Sales up at MSD while Keytruda hits survival target in late-stage trial
October 28, 2015Research and Development, Sales and Marketing MSD, Merck, financial results, keytruda, pembrolizumab
Worldwide sales at MSD were $10.1 billion in the third quarter of 2015, a 4% increase after accounting for the …
COMPANY PROFILE: The secrets of that Merck rebrand
October 23, 2015Medical Communications, Sales and Marketing Merck, branding, communications, corporate logo, reputation
Merck’s recent rebrand may have left many scratching their heads, as the company moved away from the clinical professionalism of …
Physicians Interactive acquires Univadis portal
October 22, 2015Medical Communications, Sales and Marketing Merck, Physicians Interactive, Univadis
Digital marketing firm Physicians Interactive (PI) has acquired the Univadis medical information platform, in a move which it says creates …
Ablynx and Merck begin immuno-oncology collaboration
October 15, 2015Research and Development Ablynx, Merck, immuno-oncology, nanobody, proof of concept
Ablynx has achieved a pre-clinical proof-of-concept with a nanobody construct as part of its immuno-oncology collaboration with Merck – triggering …
